Pathios Therapeutics
Pathios Therapeutics is a clinical-stage oncology and immunology drug discovery and development company based in Oxfordshire, United Kingdom, founded in 2017. The company develops small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to counteract the immunosuppressive tumor microenvironment; its lead asset PTT-4256 is a first-in-class GPR65 inhibitor now in a Phase 1/2 clinical trial. Backed by Canaan, Brandon Capital, and a strategic investment from Bristol Myers Squibb, Pathios is a research-stage biotech with no public API, developer platform, or technical integration surface. This profile was surfaced as a portfolio company of canaan-partners and processed by the enrichment pipeline, which confirmed there is no API surface to catalog.
Pathios Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Immunology.
Pathios Therapeutics’ developer surface includes product news and 4 more developer resources.
Kin Score
Resources
Operate 1
Status, limits, changes, and where to get help
Company 4
The organization behind the API